BioCorRx (BICX) Stock Price
BioCorRx Price
Revenue at BioCorRx has contracted by 18.7% per year over the past 14 years to 7,700.00 USD. For BioCorRx, the net margin of -66,313.0% is down versus -2,891.7% a few years ago. The stock trades about 350% above its 52-week low.
BioCorRx stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of BioCorRx over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how BioCorRx stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing BioCorRx's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | BioCorRx Price |
|---|---|
| 9/4/2026 | 0.21 USD |
| 9/3/2026 | 0.21 USD |
| 9/2/2026 | 0.21 USD |
| 9/1/2026 | 0.21 USD |
| 8/31/2026 | 0.21 USD |
| 8/28/2026 | 0.20 USD |
| 8/27/2026 | 0.20 USD |
| 8/26/2026 | 0.16 USD |
| 8/25/2026 | 0.22 USD |
| 8/24/2026 | 0.22 USD |
| 8/21/2026 | 0.22 USD |
| 8/20/2026 | 0.24 USD |
| 8/19/2026 | 0.25 USD |
| 8/18/2026 | 0.24 USD |
| 8/17/2026 | 0.24 USD |
| 8/14/2026 | 0.15 USD |
| 8/13/2026 | 0.28 USD |
| 8/12/2026 | 0.28 USD |
| 8/11/2026 | 0.28 USD |
| 8/10/2026 | 0.30 USD |
| 8/7/2026 | 0.30 USD |
| 8/6/2026 | 0.30 USD |
| 8/5/2026 | 0.30 USD |
| 8/4/2026 | 0.25 USD |
| 8/3/2026 | 0.28 USD |
| 7/31/2026 | 0.26 USD |
| 7/30/2026 | 0.30 USD |
| 7/29/2026 | 0.30 USD |
| 7/28/2026 | 0.30 USD |
| 7/27/2026 | 0.35 USD |
BioCorRx Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
BioCorRx Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEB USD |
|---|
| REVENUE GROWTH% |
| EBITB USD |
| EBIT MARGIN% |
| NET INCOMEM USD |
| NET INCOME GROWTH% |
| SHARESM |
| 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025e | 2026e | 2027e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | – | – | – | – | – | – | 0.71 | 0.99 | 1.30 |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | 39.58 | 30.78 |
| – | – | – | -0.01 | – | – | – | -0.01 | -0.01 | -0.01 | – | – | -0.01 | -5.61 | -7.25 | -7.38 |
| – | – | -300.00 | – | – | – | – | – | – | – | – | – | – | -789.58 | -731.48 | -569.52 |
| – | -3.00 | -3.00 | -4.00 | -5.00 | -29.00 | -6.00 | -6.00 | -3.00 | -5.00 | -4.00 | -3.00 | -5.00 | -2.00 | -2.00 | -1.00 |
| – | – | – | 33.33 | 25.00 | 480.00 | -79.31 | – | -50.00 | 66.67 | -20.00 | -25.00 | 66.67 | -60.00 | – | -50.00 |
| 1.06 | 1.17 | 1.39 | 1.55 | 1.70 | 2.33 | 2.51 | 3.52 | 5.38 | 6.49 | 7.20 | 8.34 | 10.46 | 10.46 | 10.46 | 10.46 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales BioCorRx generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue BioCorRx retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare BioCorRx's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares BioCorRx has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against BioCorRx's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
BioCorRx stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
BioCorRx Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
BioCorRx business model & stock analysis
BioCorRx SWOT Analysis
Strengths
[ { "heading": "1.", "text": "Innovative" }, { "heading": "BioCorRx", "text": "Inc" } ]
[ { "heading": "2.", "text": "Strong" }, { "heading": "The", "text": "company" } ]
[ { "heading": "3.", "text": "Strategic" }, { "heading": "BioCorRx", "text": "Inc" } ]
Weaknesses
[ { "heading": "1.", "text": "Limited" }, { "heading": "Although", "text": "BioCorRx" } ]
[ { "heading": "2.", "text": "Dependence" }, { "heading": "The", "text": "company's" } ]
[ { "heading": "3.", "text": "Limited" }, { "heading": "BioCorRx", "text": "Inc" } ]
Opportunities
[ { "heading": "1.", "text": "Growing" }, { "heading": "There", "text": "is" } ]
[ { "heading": "2.", "text": "Potential" }, { "heading": "As", "text": "addiction" } ]
[ { "heading": "3.", "text": "Technological" }, { "heading": "Advancements", "text": "in" } ]
Threats
[ { "heading": "1.", "text": "Intense" }, { "heading": "The", "text": "addiction" } ]
[ { "heading": "2.", "text": "Regulatory" }, { "heading": "The", "text": "company" } ]
[ { "heading": "3.", "text": "Economic" }, { "heading": "Economic", "text": "downturns" } ]
BioCorRx Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
BioCorRx historical P/E ratio, EBIT multiple, and P/S ratio
BioCorRx annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
BioCorRx shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
BioCorRx stock splits
BioCorRx Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 8/12/2026 | -0.05USD | - | 244.80 MUSD | - | 2026 Q2 |
| 5/13/2026 | -0.06USD | - | 224.40 MUSD | - | 2026 Q1 |
| 3/30/2026 | -0.06USD | - | 204.00 MUSD | - | 2025 Q4 |
| 11/14/2025 | -0.06USD | - | 193.80 MUSD | - | 2025 Q3 |
BioCorRx shareholder structure
| % | Name |
|---|---|
52.63779% | |
21.28717% | |
13.27560% | |
8.06155% | |
1.50140% | |
0.90207% |
BioCorRx Executives and Management Board
5 members · avg. age 62 · 40 % women
Ms. Lourdes Felix (57)
Chief Executive Officer, Chief Financial Officer, Director · since 2012
549,846.00 USD
Management
Mr. Louis Lucido (76)
President, Director · since 2019
Board of Directors
Mr. Kent Emry (57)
Independent Director · since 2013
Ms. Luisa Ingargiola (57)
Independent Director
Mr. Joseph Galligan (65)
Independent Director
BioCorRx Supply Chain
BioCorRx Supply Chain
Correlation: how closely stock prices move together
| # | Name | Trend | |||
|---|---|---|---|---|---|
| 1 | — | — | — |
Frequently asked questions about BioCorRx
The business model of BioCorRx Inc revolves around providing innovative solutions for the treatment of substance abuse and addiction. The company specializes in developing and commercializing behavioral healthcare products and services. BioCorRx Inc offers the BioCorRx Recovery Program, which combines medication-assisted treatment with counseling and peer support. This comprehensive approach aims to help individuals overcome substance abuse by addressing the underlying factors contributing to addiction and promoting long-term recovery. By integrating medical and behavioral components, BioCorRx Inc strives to provide effective solutions for patients seeking to break free from addiction.
BioCorRx Inc is primarily active in the healthcare and pharmaceutical industries.
The main competitors of BioCorRx Inc in the market include pharmaceutical companies, such as Pfizer Inc, Johnson & Johnson, and Novartis AG. Other competitors in the addiction treatment industry include Alkermes plc and Indivior Inc. These companies operate in the same market, offering various products and services for addiction treatment. BioCorRx Inc, a leader in medication-assisted treatment solutions, competes with these companies through its innovative treatment program, BioCorRx Recovery.
BioCorRx Inc is a pharmaceutical company specializing in innovative addiction treatment solutions. Established in 2008, BioCorRx is dedicated to developing effective medications and programs to support those struggling with alcohol and opioid dependencies. The company focuses on combining its proprietary medication, known as the BioCorRx® Recovery Program, with cognitive-behavioral therapy to enhance patient outcomes and reduce relapse rates. With a mission to improve the lives of individuals battling addiction, BioCorRx Inc strives to provide comprehensive and personalized treatment options. Through its commitment and innovative approach, BioCorRx Inc has positioned itself as a leading player in the addiction treatment industry.
BioCorRx Inc, a leading pharmaceutical company, has accomplished several significant milestones in recent years. One of their key achievements includes the development and commercialization of their flagship product, the BioCorRx Recovery Program, which offers a unique, non-addictive approach to treating substance abuse. The company has also made remarkable strides in expanding their distribution networks, forging partnerships with healthcare professionals, and achieving regulatory approvals for their innovative products. Moreover, BioCorRx Inc has consistently demonstrated a commitment to research and development, continually exploring new avenues for improving addiction treatment. These accomplishments highlight BioCorRx Inc's dedication to revolutionizing the field of substance abuse recovery.
BioCorRx Inc is primarily present in the United States. Recognized as a leader in substance use disorder treatment, BioCorRx operates its headquarters in Anaheim, California. With a focus on developing innovative solutions for addiction recovery, the company's presence spans the entire US territory. BioCorRx Inc is dedicated to helping individuals overcome addiction and promoting healthier lives.
BioCorRx Inc represents a strong set of values and a dedicated corporate philosophy. The company is committed to providing innovative solutions in the field of substance use disorder treatment. BioCorRx focuses on developing safe and effective approaches to help individuals overcome addiction and reclaim their lives. With a patient-centric approach, the company aims to provide comprehensive programs that combine medication-assisted treatment with behavioral support. BioCorRx exemplifies integrity, compassion, and a commitment to improving the well-being of individuals struggling with addiction. Through their cutting-edge solutions, BioCorRx Inc strives to make a positive impact in the field of addiction treatment and contribute to the overall betterment of society.
Converted at the current exchange rate, the BioCorRx share trades at 0.18 EUR (0.21 USD).
BioCorRx Inc is a leading biotechnology company that develops innovative health solutions for the treatment of addiction disorders. The company specializes in the development and sale of medications for the treatment of drug and alcohol addiction. The company has two different divisions: BioCorRx Pharmaceuticals and BioCorRx Health. BioCorRx Pharmaceuticals focuses on the research, development, and marketing of naltrexone micro-implants for use in alcohol and opioid addiction. These micro-implants are small, biocompatible pellets that are implanted under the skin to allow for continuous release of naltrexone, reducing withdrawal symptoms. BioCorRx Pharmaceuticals also holds a license for the development of buprenorphine implants for the treatment of opioid addiction. The second division, BioCorRx Health, offers a unique integrative health solution for the treatment of addiction disorders. This program includes a variety of services, including program guidance, phone support, online courses, nutritional counseling, exercise therapy, and acupuncture. The program is based on the BioCorRx Recovery Formula, a patented approach that is truly personalized to the patient and their needs. In addition, BioCorRx Inc offers a range of additional products that help reduce addictive behavior and enhance the success of the program. These include capsules for support during withdrawal, special supplements for patients with N-acetylcysteine deficiency, and enhanced vitamin and mineral supplements. BioCorRx Inc has established a strong presence in the US market and is expanding its global presence. The company has formed strategic partnerships with distribution partners to market its products and services worldwide. BioCorRx has also built excellent relationships with addiction researchers, medical professionals, and leading addiction treatment centers. The business model of BioCorRx Inc is based on two pillars: the marketing of patented medications for the treatment of addiction disorders and the sale of integrative health solutions. The company aims to offer a complete, integrated program for the treatment of addiction disorders, which includes both pharmacological treatments and supportive services. Due to the high demand for effective addiction treatments and the high demand for innovative solutions, BioCorRx Inc's business is promising. The company is well positioned to continue growing and dominate the addiction treatment market. The translation is as follows: BioCorRx Inc is a leading biotechnology company that develops innovative health solutions for the treatment of addiction disorders. The company specializes in developing and selling medications to treat drug and alcohol addiction. The company has two divisions: BioCorRx Pharmaceuticals and BioCorRx Health. BioCorRx Pharmaceuticals focuses on researching, developing, and marketing naltrexone micro-implants for alcohol and opioid addiction. These micro-implants are small, biocompatible pellets implanted under the skin to release naltrexone continuously and reduce withdrawal symptoms. BioCorRx Pharmaceuticals also holds a license to develop buprenorphine implants for opioid addiction. BioCorRx Health offers a unique integrative health solution for addiction treatment, including program guidance, phone support, online courses, nutrition counseling, exercise therapy, and acupuncture. The program is based on the BioCorRx Recovery Formula, a patented approach tailored to each patient's needs. Additionally, BioCorRx Inc provides products to reduce addictive behavior and enhance program success. These include withdrawal support capsules, special supplements for N-acetylcysteine deficiency, and improved vitamin and mineral supplements. With a strong presence in the US market and plans for global expansion, BioCorRx Inc has formed strategic partnerships to market its products and services worldwide. The company has also established relationships with addiction researchers, medical professionals, and leading addiction treatment centers. BioCorRx Inc's business model focuses on marketing patented addiction medications and selling integrative health solutions. The company strives to offer a comprehensive program that combines pharmaceutical treatments with supportive services. Given the high demand for effective addiction treatments and innovative solutions, BioCorRx Inc is well positioned for growth and market dominance in addiction treatment.
The expected revenue of BioCorRx is 991.29 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of BioCorRx is -2.24 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of BioCorRx is currently -0.98. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the BioCorRx stock.
The price-to-sales ratio (P/S) of BioCorRx is currently 0.00. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the BioCorRx stock.
The Eulerpool Quality Score for BioCorRx is 2/10.
The ISIN of BioCorRx is US09073C2052. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of BioCorRx is A1XERB. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of BioCorRx is BICX. The ticker symbol is used to trade BioCorRx shares on the stock exchange.
BioCorRx paid dividends every year for the past 0 years.
BioCorRx is assigned to the 'Health' sector.
The dividends of BioCorRx are distributed in USD.
BioCorRx stock
BioCorRx Peer Group
BioCorRx Ticker
BioCorRx FIGI
All fundamentals and in-depth analysis of BioCorRx
Our stock analysis for BioCorRx stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of BioCorRx. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.